Table 2. Renal outcomes by period

Composite Clinical Outcomes (primary outcomes)
Period 1 (AASK Trial)
    • G1: the occurrence of a 25 ml/min per 1.73 m2 or 50% reduction in GFR from trial baseline, ESRD (dialysis or transplantation), or death
    • G2: the occurrence of a 25 ml/min per 1.73 m2 or 50% reduction in GFR from trial baseline or ESRD (dialysis or transplantation)
Period 2 (AASK Trial and AASK cohort)
    • S1: Doubling of serum creatinine from trial baseline, ESRD (dialysis or transplantation), or death
    • S2: Doubling of serum creatinine from trial baseline or ESRD (dialysis or transplantation)
Period 3 (AASK Cohort)
    • S1: Doubling of serum creatinine from cohort baseline, ESRD (dialysis or transplantation), or death
    • S2: Doubling of serum creatinine from cohort baseline or ESRD (dialysis or transplantation)
GFR Slope (secondary outcome):
Period 1 (AASK Trial)
    • Mean slope from serial GFR measurements (125I-iothalamate clearance)
Period 2 (AASK Trial and AASK Cohort) and period 3 (AASK Cohort):
    • Mean slope of estimated GFR (eGFR) in which eGFR = 329 × (Scr)−1.096 × (age)−0.294 × (0.736 for women). This equation was developed from baseline data of the AASK trial (4).
Proteinuria (secondary outcome):
Same outcomes in periods 1, 2, and 3:
    • Urine protein/urine creatinine ratio (UP/Cr), a continuous variable
    • The occurrence of UP/Cr >0.22 (roughly 300 mg/day of proteinuria)
    • The occurrence of UP/Cr >0.66 (roughly 1 g/day of proteinuria)